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Protein tyrosine phosphatase non-receptor type 2 (PTPN2) plays a pivotal role in
immune homeostasis and has been associated with human autoimmune and chronic
inflammatory diseases. Though PTPN2 is well-characterized in lymphocytes, little is
known about its function in innate immune cells. Our findings demonstrate that dendritic
cell (DC)-intrinsic PTPN2 might be the key to explain the central role for PTPN2 in
the immune system to maintain immune tolerance. Partial genetic PTPN2 ablation in
DCs resulted in spontaneous inflammation, particularly in skin, liver, lung and kidney 22
weeks post-birth. DC-specific PTPN2 controls steady-state immune cell composition
and even incomplete PTPN2 deficiency in DCs resulted in enhanced organ infiltration of
conventional type 2 DCs, accompanied by expansion of IFNγ-producing effector T-cells.
Consequently, the phenotypic effects of DC-specific PTPN2 deficiency were abolished
in T-cell deficient Rag knock-out mice. Our data add substantial knowledge about the
molecular mechanisms to prevent inflammation and maintain tissue tolerance.
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INTRODUCTION
Immune tolerance is indispensable to maintain tissue homeostasis and to avoid autoimmune
responses. Dendritic cells (DCs) are key regulators of tolerance and controlled immune reactions.
DCs sense danger signals (e.g., from invading pathogens) and convert them into activating signals
for adaptive immune cells (1), thus holding a key position between innate and adaptive immunity.
DC activation is dictated and balanced by molecular and genetic mechanisms and DC reactions
are primarily shaped by their state of activation (2). Thus, a deeper understanding of the key
mechanisms that regulate DC activation and subsequent induction, promotion, and regulation of
immune responses provides fundamental insights into human pathology of inflammatory diseases.
Genome-wide association studies (GWAS) identified variants within the gene locus encoding
protein tyrosine phosphatase non-receptor type 2 (PTPN2; also known as T cell protein tyrosine
phosphatase [TC-PTP]) to be associated with chronic inflammatory and autoimmune diseases,
including type 1-diabetes, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, Crohn’s
disease, and celiac disease (3–5). First insights into mechanisms of this considerable range of
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disease associations came from the observation that PTPN2
negatively regulates pro-inflammatory signaling cascades (6–
9). PTPN2-deficient (Ptpn2−/−) mice display severe immune
defects with progressive systemic inflammation which is lethal
within 5 weeks after birth demonstrating the important role of
PTPN2 in immune regulation (10, 11).
PTPN2 is ubiquitously expressed (12) and its role in regulating
inflammatory signaling has been demonstrated in a broad
range of immune cells (7, 13, 14) and intestinal epithelial
cells (8). However, it remains poorly studied how PTPN2 in
specific cell types contributes to the correlation with human
diseases or the inflammatory phenotype in mice. Studies focusing
on T cells identified PTPN2 as important anti-inflammatory
regulator, and its deletion in T cells promoted T cell activation
leading to systemic pro- and auto-inflammatory reactions (13,
15). In intestinal epithelial cells, loss of PTPN2 promotes
inflammatory cytokine secretion and compromises epithelial
barrier function (8), and splenic macrophages from Ptpn2−/−
mice are hyperresponsive to lipopolysaccharide (LPS), suggesting
altered myeloid cell function (10).
In contrast, the role of PTPN2 in DCs has not been studied.
However, the expression profile of PTPN2 and the driving role of
DCs in initiating tissue inflammation inmice and human patients
suggest that PTPN2 might play a central role in maintaining
DC tolerance and immune homeostasis. Expression of PTPN2
is induced by inflammatory cytokines, including interferon-γ
(IFNγ) and TNF (7, 8) and it acts as a negative feedback inhibitor
of IFN-γ and cellular stress-induced signaling cascades (16),
including signaling transducer and activator of transcription
(STAT) molecules STAT1 and STAT3, mitogen activated
protein kinase MAPK p38, c-Jun N-terminal kinase JNK, and
ERK (16–19).
Unequivocal evidence has demonstrated a key role of
DCs in several PTPN2-associated inflammatory diseases (2,
20). Understanding the role of altered DC distribution or
disturbed DC function may provide targetable mechanisms
for the development of new therapeutic strategies, e.g.,
targeting host-pathogen interactions or promoting clearance of
invading pathogens.
Our experiments unveil a key role for PTPN2 in maintaining
DC-mediated tissue tolerance as well as exerting an important
anti-inflammatory role bymaintaining immune cell homeostasis.
MATERIALS AND METHODS
Mouse Strains
All mice were on a C57BL/6 background and housed under
specific pathogen-free (SPF) conditions with food and
water ad libitum. Mice expressing Cre recombinase under
control of the CD11c promoter (CD11cCre-eGFP mice)
were purchased from Jackson, RAG2−/− mice from Janvier,
C57BL/6 mice featuring PTPN2 allele 3 flanked by loxP
sequences (PTPN2fl/fl mice) from EUCOMM. PTPN2fl/fl ×
CD11cCre mice were generated by crossing PTPN2fl/fl mice
with CD11cCre-eGFP mice. PTPN2fl/fl × CD11cCre mice were
crossed with RAG2−/− mice to obtain PTPN2fl/fl × CD11cCre
× RAG−/− mice. For all experiments, littermate controls
were used, and males and females were distributed in equal
number. The local animal welfare commission of the Cantonal
Veterinary Office Zurich approved all animal experiments in
this study.
Antibiotic Treatment
For antibiotic treatment, breeding cages were provided
with drinking water containing antibiotics ad libitum
and offspring kept on antibiotics until tissue collection
at the age of 5 weeks. Drinking water was supplemented
with an antibiotic mixtures consisting of neomycin 1 g/L
(Sigma-Aldrich), vancomycin 0.5 g/L (Sigma-Aldrich),
ampicillin 1 g/L (Sigma-Aldrich), and metronidazole 1 g/L
(Sigma-Aldrich). 0.2% (w/v) aspartame (Sigma-Aldrich)
was added to the drinking water. Water was renewed once
per week.
Tissue Harvesting and Cell Preparation
Mice were sacrificed by CO2 inhalation, transcardiac perfusion
was performed with PBS prior to collection of skin, liver, lung,
kidney, and spleen. Liver, lung, kidney, and spleen were digested
with Collagenase Type IV (0.4 mg/mL; from Clostridium
histolyticum, Sigma Aldrich) in HBSS (Sigma Aldrich)
containing 10% FCS for 45min at 37◦C; skin was digested with
Collagenase Type IV (1 mg/mL; from Clostridium histolyticum,
Sigma-Aldrich) and DNase (0.1 mg/ml, Sigma-Aldrich) in RPMI
(Thermo Fisher Scientific) containing 5% FCS (Brunschwig)
for 90min at 37◦C. The samples were homogenized using an
18 gauge needle and the homogenate filtered through a 70µm
cell strainer. For liver homogenates, digestion/homogenization
was followed by a gradient centrifugation with 30% Percoll (GE
Healthcare Life Sciences) in PBS (23,500 × g for 30min at 4◦C
without brakes). For liver, lung, kidney, and spleen, erythrocyte
lysis was performed using ammonium-chloride-potassium
(ACK) buffer (150mM NH4Cl, 10mM KHCO3, 0.1mM
Na2EDTA). The samples were then stained with fluorescence
cytometry antibodies.
Flow Cytometry
Cells were incubated with primary antibodies in PBS for 30min
at 4◦C and washed with PBS. Cells were fixed and permeabilized
with BD Cytofix/CytopermTM for 20min at 4◦C, and washed
with Perm buffer before intracellular labeling in Perm buffer for
30min at 4◦C, followed by final washing with Perm buffer. For
intracellular cytokine staining, cells were incubated for 4 h at
37◦C in RPMI containing 10% FCS with PMA (50 ng/ml, Sigma-
Aldrich), Ionomycin (1µg/ml, Sigma-Aldrich), and Brefeldin
A (1µg/ml, Sigma-Aldrich). Samples were resuspended in
PBS and analyzed by flow cytometry on an LSR II Fortessa
(equipped with 405, 488, 561, and 640 nm laser lines; BD) or BD
FACSymphony (equipped with 355, 405, 488, 561, and 639 nm
laser lines) with FACS Diva Software. Cell sorting was performed
using a FACSAria III (BD). Before data acquisition, PMT
voltages were adjusted manually to reduce fluorescence spillover,
and single-stain controls were acquired for compensation
matrix calculation. The following murine antibodies were
used: CD8-BUV805 (clone 53-6.7, BD Biosciences, #564920),
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CD62L-BUV737 (clone MEL-14, BD Biosciences, #565213),
CD11b-BUV661 (cloneM1/70, BD Biosciences, #565080), Ly6G-
BUV563 (clone 1A8, BD Biosciences, #560757), CD4-BUV563
(clone GK1.5, BD Biosciences, #565709), CD24-BUV496 (clone
M1/69, BD Biosciences, #564664), CD45-BUV395 (clone 30-F11,
BD Biosciences, #564279), CD90.2-BV785 (clone 30-H12,
BioLegend, #105331), CD3-BV785 (clone 17A2, BioLegend,
#100232), NK1.1-BV785 (clone PK136, BioLegend, #108749),
B220-BV785 (clone RA3-6B2, BioLegend, #103246), Ly6C-
BV711 (clone hk1.4, BioLegend, #128037), NK1.1-BV711 (clone
PK136, BioLegend, #108745), CD4-BV711 (clone GK1.5, BD
Biosciences, #563050), CD80-BV650 (clone 16-10A1, BioLegend,
#104732), TNF-BV650 (clone MP6-XT22, BioLegend, #506333),
CD4-BV650 (clone RM4-5, BioLegend, #100546), Ly6C-
BV605 (clone HK1.4, BioLegend, #128035), CD62L-BV605
(clone MEL-14, BioLegend, #104437), IL10-BV605 (clone
RA3-6B2, BioLegend, #505031), B220-BV570 (clone RA3-6B2,
BioLegend, #103237), Ly6G-BV510 (clone 1A8, BioLegend,
#127633), CD25-BV510 (clone PC61, BioLegend, #102041),
CD45-BV510 (clone 30-F11, BioLegend, #103138), CD45-
PB (clone 30-F11, BioLegend, #103126), gdTCR-eFluor450
(clone GL-3, Thermo Fisher Scientific, #48-5711-82), CD11c-
eFluor450 (clone N418, Themo Fisher Scienctific, #48-0114-82),
CD44-eFluor450 (clone IM7, BioLegend, #103020), pSTAT3-
BV421 (clone 13A3-1, BioLegend, #651010), FoxP3-PB (clone
MF14, BioLegend, #126410), CD3-PerCP (clone 145-2C11,
BioLegend, #100326), CD24-PerCP-Cy5.5 (clone M1/69,
BioLegend, #101824), IRF8-PerCP-Cy5.5 (clone V3GYWCH,
Thermo Fisher Scientific, #46-9852-82), CD8-PerCP-Cy5.5
(clone 53-6.7, eBioscience, #45-0081-82), gdTCR-PE-Cy7
(clone GL2, BioLegend, #118124), CD45-PE-Cy7 (clone 30-
F11, BioLegend, #103114), IFNg-PE-Cy7 (clone XMG1.2,
eBioscience, #25-7311-82), CD11c-PE-Cy7 (clone N418,
Thermo Fisher Scientific, #25-0114-81), B220-PE-Cy7 (clone
RA3-6B2, BD Pharmigen, #552772), CD11c-PE-Cy5.5 (clone
N418, Themo Fisher Scientific, #35-0114-82), F4/80-PE-Cy5
(clone BM8, BioLegend, #123112), CD86-PE-Cy5 (clone GL1,
Thermo Fisher Scientific, #15-0862-82), CD8-PE-CF594 (clone
53-6.7, BD Biosciences, #562283), CD3-PE-TexasRed (clone
145-2C11, BD Biosciences, #562286), CD44-PE-Dazzle594
(clone 3/23, BioLegend, #124630), F4/80-PE-eFluor610 (clone
BM8, eBioscience, #61-4801-82), pSTAT1-PE (clone A15158B,
BioLegend, #686404), IRF4-PE (clone IRF4.3E4, BioLegend,
#646404), CD25-PE (clone PC61, BD Pharmigen, #553866),
CD64-PE (clone X54-5/7.1, BioLegend, #139304), F4/80-PE
(clone BM8, BioLegend, #123110), CD80-PE (clone 16-10A1,
Thermo Fisher Scientific, #12-0801-82), TCRbeta-APC-Cy7
(clone H57-697, BioLegend, #109220), CD45.2-APC-eFluor780
(clone 102, Themo Fisher Scientific, #47-0454-082), CD25-
APC-Cy7 (clone PC61, BioLegend, #102025), Zombie NIRTM
Fiaxable Viability Kit (BioLegend, #423106), MHCII-AF700
(clone M5/114.15.2, BioLegend, #107622), CD19-APC (clone
1D3/CD19, BioLegend, #152410), F4/80-AF647 (clone CI:A3-
1, BioRad, #MCA497A647), FoxP3-APC (clone FJK-16s,
eBiosciences, #17-5773-82), CD11b-APC (clone M1/70,
Themo Fisher Scientific, #17-0112-82), CD3-APC (clone 17A2,
BioLegend, #100235). Data analysis was performed using FlowJo
10.0.x (BD). Populations of interest were manually pre-gated in
FlowJo software with applied compensation correction. Then
we combined equal numbers of randomly selected cells from
each group and visualized data using t-Distributed Stochastic
Neighbor Embedding (t-SNE).
Cell Sorting
Cells were sorted using a FACSAria III (BD) (equipped
with 405, 488, 561, and 633 nm lasers) and a 70µm nozzle
using 4-way purity mask. Post-sort purity was > 95%.
Cell populations were sorted based on surface marker
expression: T-cells (CD3+B220−), B cells (CD3−B220−),
Macrophages (CD3−B220−F4/80+), and Dendritic
cells (CD3−B220−F4/80−MHCII+CD11c+).
ELISA
Serum was stored at −80◦C until use. ELISA kit detecting
mouse IgG was obtained from Thermo Fisher Scientific, mouse
anti-dsDNA from Alpha Diagnostic International. For the kit
detecting mouse anti-dsDNA, serum was diluted 1:100. Assays
were performed according to the manufacturer’s instructions.
Cytokine levels were measured using Bio-Plex ProTM Mouse
Cytokine Group I Panel 23-plex (BioRad) according to the
manufacturer’s instructions.
Generation and Stimulation of Bone
Marrow-Derived Dendritic Cells
Bonemarrow-derived dendritic cells were generated in vitro from
bone marrow cells as described (21). In brief, bone marrow cells
were flushed from femur and tibia and cultured in complete
RPMI medium supplemented with GM-CSF for 7 days. Medium
was renewed on day 4 of the culture. For DC activation, cells
were stimulated for 30min or 24 h with IFNγ (100 ug/mL, LuBio
Science) or lipopolysaccharide (LPS) (1µg/mL, InvivoGen).
Western Blotting
Cells were lysed inM-PER lysis buffer (Thermo Fisher Scientific),
mixed with NUPAGE R© 4× LDS Sample Buffer (life technologies)
and boiled for 5min at 95◦C. Proteins were separated on
SDS-polyacrylamide gels by electrophoresis and transferred
onto nitrocellulose membranes. Membranes were blocked with
blocking solution (3% milk, 1% BSA) and primary antibody
diluted in blocking solution was added over night at 4◦C. After
washing, HRP-labeled secondary antibody in blocking solution
was added for 30min followed by washing. The following
antibodies were used: phospho-STAT1 (Tyr701) (CellSignaling,
7649S), total STAT1 (CellSignaling, 9172S), anti-rabbit HRP
secondary antibody (Santa Cruz, sc-2357).
Proteins were detected using an enhanced chemiluminescence
detection kit (Thermo Fisher Scientific) and densitometric
analysis was performed using ImageJ software.
RNA Extraction and RT-PCR
Cells were lysed in RLT buffer (Qiagen) and total RNA was
isolated using RNeasy Mini Kit (Qiagen). RNA concentration
was measured on a NanoDrop (Thermo Fisher Scientific)
by absorbance at 260 and 280 nm. Complementary DNA
Frontiers in Immunology | www.frontiersin.org 3 August 2020 | Volume 11 | Article 1856
Hering et al. PTPN2 in Dendritic Cells
(cDNA) was synthesized using a High-Capacity cDNA Reverse
Transcription Kit (Thermo Fisher Scientific) following the
manufacturer’s instructions.
Statistical Analysis
All statistical analyses were carried out using GraphPad
Prism v.8 (GraphPad Software). Between-group differences
were determined by Mann-Whitney U-test. One-way ANOVA
Turkey’s multiple comparison test was used. A P-value<0.05 was
considered statistically significant.
RESULTS
Organ-Resident DCs Require PTPN2 to
Control the Composition of Immune Cell
Populations
The ubiquitous contribution of DCs in diseases associated with
aberrant PTPN2 function invoked the hypothesis that PTPN2
might affect DC activation. We investigated this hypothesis by
generating mice specifically lacking PTPN2 in DCs (PTPN2fl/fl
× CD11cCre mice). DCs, but not other immune cells, displayed
a 30% reduction in PTPN2 expression when compared to
cells from PTPN2fl/fl mice (Figure S1), while in macrophages,
PTPN2 expression was increased (Figure S1). As activated DCs
affect the composition of the immune cell populations in non-
lymphoid organs (22), we designed a 21-color fluorescence
cytometry surface antibody panel to assess whether loss of
PTPN2 in DCs affects immune cell populations in the skin,
liver, lung, and kidney. To detect possible adaptations over
time, 5-weeks-old, 13-weeks-old, and 22-weeks-old PTPN2fl/fl
× CD11cCre mice were investigated and meta-clustering
provided a comprehensive overview of the different immune
cell populations (Figures 1A,D,E). Data were visualized in a t-
distributed stochastic neighbor embedding (t-SNE)map and cells
categorized using a FlowSOM-guided algorithm (23). Traditional
manual gating of the flow cytometry data and median marker
expression for identified clusters confirmed the identity of the
cell populations (Figure S2). In 5-weeks-old mice, we found
changes in the proportions of myeloid and lymphoid immune
cells in skin, liver, lung, and kidney (Figure 1A). Proportional
changes were observed among all leukocytes and distinct
populations showed clear qualitative differences as observed in
shifted clustering in the t-SNE maps. This resembles the altered
tissue immune compartment observed in human patients with
inflammatory diseases, such as systemic lupus erythematosus
or rheumatoid arthritis (24, 25). Overall, the number of
leukocytes was increased in PTPN2fl/fl × CD11cCre mice across
all analyzed organs (Figure 1B), with increased proportions
of Ly6G+ neutrophils and Ly6C+ monocytes but a relative
reduction of F4/80+CD64+ macrophages and MHCII+CD11c+
conventional DCs (cDCs; Figure 1C). Similar changes were
observed in 13-weeks-old (Figure 1D; Figures S3A,B) and 22-
weeks-old mice (Figures 1E, 3C,D). Together, these data show
that DC-specific loss of PTPN2 does not only affect specific
immune cell populations or DCs, but has a broad effect on
immune cells of the innate and adaptive immune system.
Moreover, inflammatory cell populations, such as neutrophils
and monocytes, were already affected in very young mice.
Increased cDC2 Infiltration Into Skin and
Liver Upon PTPN2 Deletion
Having characterized the general composition of immune cell
infiltrates in several organs, we focused our investigation on
cDCs. Given the increased infiltration of inflammatory cells
in skin, liver, lung, and kidney, we hypothesized that (partial)
deletion of PTPN2 might mediate preferential infiltration of
specific cDC subsets that drive inflammatory processes. In
all assessed organs we observed the presence of two distinct
cDC subtypes corresponding to cDC1s and cDC2s (26, 27)
as identified by their surface expression of CD11b and CD24
(Figure 2A) and confirmed by intracellular IRF4-IRF8 staining
(Figure 2B). Analyzing cDC1s and cDC2s across organs allowed
us to investigate the effect of loss of PTPN2 on different cDCs
populations (Figure 2C). We identified profound organ-specific
changes in cDC subsets in 5-weeks-old PTPN2fl/fl × CD11cCre
mice, characterized by an increased proportion of cDC2
restricted to skin and liver, whereas the proportions in lung and
kidney were not altered (Figure 2D). The preferential infiltration
of CD11b+ cDC2s into skin and liver persisted in 13-weeks-old
and 22-weeks-old mice (Figures 2E,F). Thus, loss of PTPN2 even
in only 30% of DCs affects infiltration and differentiation of DC
subpopulations in an organ-specific manner.
Expansion of IFNγ-Producing and Effector
T Cells in a PTPN2-Deficient Environment
Given the profound changes in innate immune cells and
specifically in cDC populations in PTPN2fl/fl × CD11cCre
mice, we further characterized downstream effects on the
adaptive immune system, namely T cell activation and cytokine
production. For this purpose, tissue resident cDCs were assessed
for their capacity to activate T cells. T cell subsets and
activation status was determined and visualized in a t-SNE
map and cell populations confirmed by traditional manual
gating (Figure 4A). In 5-weeks-old PTPN2fl/fl × CD11cCre mice
we found increased absolute numbers of infiltrating CD3+
T cells into skin, liver, lung, and kidney (Figure 3A), which
affected both, CD4+ and CD8+ subpopulations (Figure 3B).
Analysis of the activation status of T cells in skin, liver, lung,
and kidney revealed a significant reduction of naïve T cells
(CD62L+CD44−) and increased infiltration of effector T cells
(CD62L−CD44+) for both, CD4+ and CD8+ T cells across all
analyzed tissues (Figures 3C–F). Further, CD4+ and CD8+ T
cells from PTPN2fl/fl ×CD11cCre mice produced increased levels
of IFNγ (Figure 3G), which is in line with previous findings
obtained in mice lacking PTPN2 in T cells (13). In contrast,
TNF production was not affected in T cells from PTPN2fl/fl
× CD11cCre mice (Figure S4B) and there was no difference
in infiltration of FoxP3+ regulatory T cells (Figure S4C). The
increased T cell activation was also observed in 13-weeks-old
mice (Figure S4D) and to a smaller extent in 22-weeks-old mice
(Figure S4E). Together, our data reveal a downstream effect of
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FIGURE 1 | Altered immune cell populations upon partial PTPN2 deletion in DCs. Immune cells were analyzed in 5-weeks-old, 13-weeks-old, and 22-weeks-old
PTPN2fl/fl (WT) and PTPN2fl/fl × CD11cCre (KO) mice. t-SNE maps displaying live, CD45+ single cells in skin, liver, lung, and kidney. Colors correspond to
(Continued)
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FIGURE 1 | FlowSOM-guided clustering of cell populations. Pie charts represent relative numbers among CD45+ cells. (A) t-SNE maps of CD45+ cells in
5-weeks-old mice. (B) Total counts of CD45+ cells among indicated tissues in 5-weeks-old-mice. (C) Relative numbers of neutrophils, monocytes, macrophages, and
DCs among CD45+ cells among indicated tissues in 5-weeks-old mice. (D,E) t-SNE maps of CD45+ cells in 13-weeks-old (D) and 22-weeks-old (E) mice. Data are
representative of two independent experiments with n ≥ 4 mice (A–E). *p < 0.05; **p < 0.01 [two-tailed Mann Whitney test (C)]. Data are shown as mean ± s.d. (C).
PTPN2-deficient DCs on T cells resulting in increased tissue
infiltration, and activation/IFNγ production of T cells.
Loss of PTPN2 in DCs Causes
Spontaneous Inflammation in Skin and
Liver
Our results on altered composition of immune cell infiltrates
together with increased T cell activation/IFNγ production raised
the question whether the continuous exaggerated activation of
the innate and adaptive immune system on a systemic level
ultimately leads to loss of tissue tolerance and the development
of inflammation in PTPN2fl/fl × CD11cCre mice. Indeed at the
age of 22–25 weeks, around 40% of PTPN2fl/fl × CD11cCre
mice developed spontaneous inflammation of the skin and
liver. Histologic assessment of hematoxylin and eosin stained
tissue sections showed inflammatory infiltrates in the skin and
kidney, as well as inflammation and tissue damage in the
liver (Figures 4A–C). In addition, all mice displayed enlarged
spleens even in absence of overt tissue inflammation (Figure 4D),
indicating subclinical systemic inflammation. Further, we found
increased levels of circulating IgG and anti-dsDNA in the
serum of 5-weeks-old PTPN2fl/fl × CD11cCre mice (Figure 4E).
Notably, 5-weeks-old mice with highly increased levels of dsDNA
in the serum developed severe skin and liver inflammation at
later age. After onset of inflammation, PTPN2fl/fl × CD11cCre
mice displayed elevated levels of AST and ALT aminotransferases
indicating liver damage (Figure 4F). In addition, we detected
increased levels of RANTES in 5-weeks-old young mice, whereas
other inflammatory markers, such as MIP-1α, MIP-1β, and
TNF were unaltered in those mice, but slightly increased in
inflamed 25-weeks-old mice (Figure 4G). The collective of these
inflammatory markers in aging mice indicates gradual loss of
immune tolerance. Thus, PTPN2 in DCs exerts an important
anti-inflammatory role to maintain tissue tolerance and even
incomplete DC-specific loss of PTPN2 causes inflammation in
aged mice.
Spontaneous Multiorgan Inflammation Is
Dependent on Lymphocytes
As PTPN2fl/fl × CD11cCre mice exhibited increased T cell
activation in several tissues, we hypothesized that the onset
of systemic inflammation in these mice was due to aberrant
lymphocyte activation. To test this hypothesis, we crossed
PTPN2fl/fl × CD11cCre mice into the RAG−/− background
since these mice are deficient for T and B cells. The increased
proportion of CD11b+ cDC2s in skin and liver of 5-weeks-
old PTPN2fl/fl × CD11cCre mice (Figure 2C) was no longer
present in PTPN2fl/fl × CD11cCre × RAG−/− mice and
frequencies of cDC1s and cDC2s were comparable between
PTPN2fl/fl × RAG−/− and PTPN2fl/fl × CD11cCre × RAG−/−
mice (Figure 5A). Further, aged PTPN2fl/fl × CD11cCre ×
RAG−/− mice did not develop skin lesions and histology of
skin, kidney, and liver tissue revealed that there were no
inflammatory infiltrates detectable (Figures 5B–D). However,
we still detected increased spleen weight in PTPN2fl/fl ×
CD11cCre × RAG−/− mice (Figure 5E). In summary, RAG-
deficiency protects mice lacking PTPN2 in DCs from the
onset of spontaneous tissue inflammation, suggesting a driving
role of lymphocytes for the observed disease phenotype in
PTPN2fl/fl × CD11cCre mice. As PTPN2fl/fl × CD11cCre mice
displayed an increase of both, B and T cells, the inflammatory
processes cannot be attributed solely to one type of lymphocytes.
However, the effect on B cells was less pronounced than
on T cells, pointing toward a primarily T cell-mediated
inflammatory phenotype.
Increased DC Activation via Upregulation
of the IFNγ-STAT1 Pathway in
PTPN2-Deficient DCs
PTPN2 regulates STAT proteins in T cells, monocytes and
intestinal epithelial cells (13), thus we investigated whether loss of
PTPN2 might increase phosphorylation of STAT proteins in DCs
as well. Indeed, we found enhanced phosphorylation of STAT1,
but not of STAT3, in PTPN2-deficient bone marrow-derived
dendritic cells (BMDCs) upon treatment with IFNγ, whereas
lipopolysaccharide (LPS) stimulation did not affect STAT1
phosphorylation (Figures 6A,B). IRF1 is a downstream target
of STAT1 and responsible for inducing DC maturation (28).
Further, IFN type I and type II are known to up-regulate the co-
stimulatory molecule CD80 on monocytes via up-regulation of
IRF1 (29). Hence, we speculated that increased phosphorylation
of STAT1might trigger aberrant DCmaturation by up-regulating
IRF1 in PTPN2-deficient DCs, leading to increased CD80/CD86
co-stimulatory molecules, which subsequently promotes T cell
activation. Indeed we detected increased expression of IRF1,
CD80, and CD86 upon IFNγ stimulation as well as up-
regulation of CD80 and CD86 upon LPS treatment in PTPN2-
deficient BMDCs (Figure 6C). In addition, we detected increased
expression of the immune-regulatory cytokines iNOS, IDO, and
PDL1 upon IFNγ treatment as well as elevated expression of
iNOS and TGFβ upon LPS stimulation (Figure S5). In line with
the in vitro findings, DCs derived from the liver, lung, and kidney
of 5-weeks-old PTPN2fl/fl ×CD11cCre mice that did not yet show
any signs of inflammation, displayed slightly increased mRNA
levels of IRF1 (Figure 6D) as well as elevated expression of CD80
and CD86, even though this up-regulation was less prominent
than in our in vitro experiments (Figure 6E), andmight reflect
the incomplete PTPN2-deletion in our mouse model. Consistent
with a generally increased activation of DCs, mRNA expression
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FIGURE 2 | Partial loss of PTPN2 increases cDC2 accumulation in skin and liver. (A) Representative flow cytometry plots for identification of CD11b+ cDC1s (brown)
and CD24+ cDC2s (green). (B) IRF4 and IRF8 expression in cDC1s and cDC2s. (C) Pie charts of the proportion of cDC1s and cDC2s across tissues in young
(5-weeks-old) PTPN2fl/fl (WT) and PTPN2fl/fl × CD11cCre (KO) mice. (D–F) Frequencies of cDC subset distribution in 5-weeks-old (D), 13-weeks-old (E), and
22-weeks-old (F) mice. Data are representative of two independent experiments with n ≥ 4 mice (C–F). *p < 0.05 [two-tailed Mann Whitney test (D–F)]. Data are
shown as mean ± s.d. (D–F).
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FIGURE 3 | PTPN2 in DCs affects T cell infiltration and activation. (A) Absolute numbers of CD3+ T cells in PTPN2fl/fl (WT) and PTPN2fl/fl × CD11cCre (KO) mice. (B)
Absolute numbers of CD4+ and CD8+ T cells. (C–F) tSNE map of CD3+ cells from 5-weeks-old mice in skin (C), liver (D), lung (E), and kidney (F). Colors correspond
to FlowSOM-guided clustering of cell populations. (C–F) Relative frequencies of T cell subsets in skin (C), liver (D), lung (E), and kidney (F). (G) Manually gated IFNγ
expression of CD4+ and CD8+ T cells. Data are representative of two independent experiments with n ≥ 4 mice (A–F). *p < 0.05; **p < 0.01 [two-tailed Mann
Whitney test (A–F)]. Data are shown as mean ± s.d. (A–F).
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FIGURE 4 | Spontaneous inflammatory infiltrates in liver and skin upon partial ablation of PTPN2 in DCs. (A–C) Representative pictures from H&E-stained sections of
skin (A), kidney (B), and liver (C) of 25-weeks-old PTPN2fl/fl (WT) and PTPN2fl/fl × CD11cCre (KO) mice. (D) Spleen weight. (E) Serum levels of IgG and anti-dsDNA
IgG. (F) Serum levels of amino transferases. (G) Serum levels of inidcated cytokines. Each dot represents one mouse [n = 9 mice (D), n ≥ 3 mice (E), n ≥ 8 mice
(F,G)]. *p < 0.05; ****p < 0.00001 [two-tailed Mann Whitney test (D–G)]. Data are shown as ± s.d. (D–G).
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FIGURE 5 | Tissue inflammation is dependent on lymphocytes. PTPN2fl/fl × CD11cCre mice were crossed to RAG2−/− mice to generate PTPN2fl/fl × CD11cCre ×
RAG−/− mice. (A) Frequencies of cDCs subsets in 5-weeks-old PTPN2fl/fl (WT), PTPN2fl/fl × CD11cCre (KO), PTPN2fl/fl × RAG−/− (WT RAG), and PTPN2fl/fl ×
CD11cCre × RAG−/− (KO RAG). (B–D) Representative pictures from H&E-stained sections of skin (B), kidney (C), and liver (D) in 25-weeks-old mice. (E) Spleen
weight in 25-weeks-old mice. Data are representative of two independent experiments [n ≥ 4 mice (A), n ≥ 9 mice (E)]. *p < 0.05; **p < 0.01; ***p < 0.001
[two-tailed Mann Whitney test (A,E)]. Data are shown as mean ± s.d. (A,E).
of IL10 was enhanced in all investigated organs, while there was
no effect on TGFβ expression (Figure S5B).
Since tissue inflammation was heterogeneous among
PTPN2fl/fl × CD11cCre mice, and PTPN2-deficient DCs
reacted stronger to the bacterial cell wall product LPS, we
speculated that tissue inflammation in PTPN2fl/fl × CD11cCre
mice might be triggered by bacteria. Indeed, treatment of
PTPN2fl/fl × CD11cCre mice with antibiotics resulted in
normalized levels of infiltrating neutrophils and monocytes in
the skin (Figure 6F). In the liver, frequencies of neutrophils
in PTPN2fl/fl × CD11cCre mice were reduced after antibiotics
treatment, and levels of monocytes were comparable to
wild-type mice (Figure 6G). Together, our data indicate that
even partial loss of PTPN2 in DCs promotes DC activation
via enhancing IFNγ-STAT1 signaling as well as elevated
response to microbial stimuli, resulting in elevated CD80 and
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FIGURE 6 | Increased DC activation via upregulation of the IFNγ-STAT1 pathway. (A–C) BMDCs were generated from PTPN2fl/fl (WT) and PTPN2fl/fl × CD11cCre (KO)
mice. (A,B) Phosphorylation levels of STAT1 and STAT3 determined by Western Blot (A) and Flow Cytometry (B). (C) mRNA expression of IFNγ pathway-associated
genes. (D) mRNA expression levels of IRF1 in lysates of indicated organs. (E) Mean fluorescence intensity (MFI) of co-stimulatory molecules on cDCs. (F,G) Relative
(Continued)
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FIGURE 6 | numbers of neutrophils and monocytes in skin (F) and liver (G) of 5-weeks-old mice after antibiotics treatment. Data are pooled from two independent
experiments (A–C), representative of two independent experiments (D), pooled from three independent experiments (E), or pooled from three independent
experiments (F,G) [n = 6 mice (A,B), n ≥ 3 mice (C), n ≥ 3 mice (D), n ≥ 10 mice (E), n ≥ 6 mice (F,G)]. *p < 0.05; **p < 0.01; ****p < 0.00001 [one-way ANOVA,
Tukey’s multiple comparison test (A–C,F,G); two-tailed Mann Whitney test (D,E)]. Data are shown as mean ± s.d (A–G).
CD86 expression, which promotes aberrant T-cell activation
and finally loss of tissue tolerance. Depletion of microbial
stimuli with antibiotic treatment normalized immune cell
infiltrates to levels comparable to that of wild-type mice in skin
and liver.
DISCUSSION
Here, we demonstrated a crucial role for DC-intrinsic PTPN2
for preventing inflammation and maintaining tissue tolerance.
PTPN2 controls tissue immune homeostasis by specifically
regulating the activation state of DCs. The phenotype observed
upon DC-specific loss of PTPN2, although incomplete, was
even broader, and triggered profound changes in the whole
immune cell landscape. Consequently, PTPN2 dysfunction in
DCs affected various myeloid and lymphoid immune cell
populations—likely due to the natural interplay between DCs
and other immune cells. The increased infiltration of T cells
and phagocytic cells, such as monocytes and neutrophils into
skin, liver, lung and kidney, indicates ongoing (subclinical)
inflammatory processes already in young mice. These excessive
inflammatory responses in mice with a partial DC-specific
PTPN2 deletion correlate well with the association of PTPN2
with a broad number of autoimmune and chronic inflammatory
diseases. Furthermore, triggering of excessive innate and adaptive
immune responses already upon partial loss of PTPN2 in DCs
highlights the central role for PTPN2 in mediating DC-induced
immune cell homeostasis.
Precise control of inflammatory responses is required to
prevent tissue damage (30). Our results indicated that PTPN2
plays a central role in DCs for regulating the interaction between
the innate and the adaptive immune system. Intriguingly,
the inflammatory response in animals with PTPN2-deficient
DCs seemed to result from an aberrant interaction between
T cells and PTPN2-deficient DCs, rather than being purely
DC mediated. In addition to systemic changes in the general
immune cell landscape, we also detected organ-specific changes
in CD24+IRF8+ cDC1 and CD11b+IRF4+ cDC2 (27, 31).
Notably, most profound changes in cDC populations were
observed in organs where inflammation occurred at later
age. In specific, increased proportions of CD11b+ cDC2 cells
were restricted to skin and liver, but not altered in lung
and kidney. This shift in cDC populations toward CD11b+
cDC2 cells was already present in young mice before any
obvious onset of tissue inflammation. This suggests that an
early, continuous infiltration of CD11b+ cDC2 cells, potentially
induced and further potentiated by exacerbated responsiveness to
microbial stimuli, promoted the development and accumulation
of inflammatory lymphocytes and ultimately the development of
severe inflammatory symptoms in aged mice.
The importance of CD11b+ cDC2s at the site of inflammation
was highlighted by the fact that PTPN2fl/fl × CD11cCre ×
RAG−/− mice, which did not develop any signs of inflammation,
showed CD11b+ cDC2 levels comparable to their wild-type
littermates, indicating a vicious circle between hyper-reactive
DC and aberrantly activated T and B cells. Absence of a shift
in cDC1/cDC2 when no lymphocytes were present highlights
the importance of PTPN2 in DCs in regulating the crosstalk
between innate and adaptive immune cells. In contrast to
increased numbers of infiltrating monocytes, the abundance
of macrophages was reduced in PTPN2fl/fl × CD11cCre mice,
which might surprise since monocytes are considered to
develop into tissue macrophages once recruited from the
blood. However, inflammation can inhibit the maturation of
monocytes, thus the general inflammatory milieu in PTPN2fl/fl
× CD11cCre mice might account for the relative decrease
in macrophages.
Several mouse lines expressing Cre recombinase under
the control of the CD11c promoter have been developed
(32, 33). These models differ in terms of target efficiency
and specificity. One commonly used mouse model has been
described to target DCs very efficiently but expression of
Cre recombinase was not restricted to CD11c+ cells but
also affected lymphocytes, NK cells and Ly6C+ myeloid cells
(32). The CD11cCre-eGFP strain used in our study exclusively
targets CD11c+ cells without affecting CD11c− cells (33).
Thus, effects on the general immune landscape are expected
to be solely mediated by targeted, although incomplete PTPN2
ablation in DCs. Use of this specific CD11cCre-eGFP-strain
allowed us to study the DC autonomous role of PTPN2 by
excluding any lymphocyte-intrinsic effects. Hence the here
observed effects on the immune cell composition, and on
T cells in specific, are clearly driven by altered function of
PTPN2-deficient DCs and not by effects of Cre-recombinase in
CD11c− cells.
The role of PTPN2 in IFNγ-STAT1 signaling and T cell
activation as well as differentiation have been addressed in
previous studies (13, 15). Our data demonstrated that increased
cytokine production, aberrant T cell activation and infiltration
of mononuclear cells resulted in tissue damage and ultimately
death in PTPN2fl/fl × CD11cCre mice. We found that already
partial loss of PTPN2 in DCs caused downstream changes in
the T cell compartment, promoting infiltration of CD4+ and
CD8+ effector T cells, as well as increased IFNγ production by
CD4+ and CD8+ T cells. However, TNF production by CD4+
and CD8+ T cells was unaltered, highlighting the role of DC-
intrinsic PTPN2 in specifically driving type 1 immune responses,
possibly via changes in the cytokines that these cells produce.
This would also explain why PTPN2-deletion only in some,
but not all DCs has a dominant effect, and why DCs that still
Frontiers in Immunology | www.frontiersin.org 12 August 2020 | Volume 11 | Article 1856
Hering et al. PTPN2 in Dendritic Cells
express PTPN2 in PTPN PTPN2fl/fl × CD11cCre mice are not
able to suppress the inflammation-promoting effect of PTPN2-
deficient DCs. The DC-mediated increase in T cell-derived IFNγ
production is in line with previous observations in T cell-specific
PTPN2 knockout mice (13) and might in turn be responsible
for the increase in IRF4+ cDC2s in PTPN2fl/fl × CD11cCre
mice. Given the persistent inflammatory environment, caused
by aberrant DCs that trigger elevated T cell activation, one
might expect to observe increased levels of all effector T cells,
including Treg cells. Nevertheless, partial PTPN2 deletion in
DCs did not manifest in an increase of Tregs, indicating that
PTPN2 deficiency renders DCs more active while reducing their
potential to induce tolerogenic responses and Treg formation
(e.g., due to the high expression of co-stimulatory molecules).
As aged PTPN2fl/fl × CD11cCre × RAG−/− mice did not show
any signs of systemic inflammation, we were able to confirm
lymphocytes as main drivers of the inflammation in PTPN2fl/fl
× CD11cCre mice.
Hypersensitivity to LPS has been shown to play an important
role in the development of the inflammatory phenotype in
Ptpn2−/− mice (10), and in PTPN2fl/fl × CD11cCre mice
the inflammatory response seems to be (at least partially)
triggered by a hyper-responsiveness of PTPN2-deficient DCs
to bacterial antigens/products. In healthy animals, LPS is
constantly produced by enteric bacteria and detoxified by
the liver. In contrast, upon liver damage, LPS and other
endotoxins can spread systemically causing an increase in
cytokine levels (34, 35). The skin provides an important
barrier and is colonized by highly diverse populations of
microorganisms, such as bacteria, fungi, and viruses, with many
of them being beneficial and providing vital functions (36,
37). Further, several common skin diseases, such as atopic
dermatitis and acne, feature a distinct microbial contribution
as well as dysregulated skin immune responses (38). This
suggests sustained exposure to natural microbial challenges,
especially in skin and liver. While these stimuli by commensals
are normally tolerated by the immune system, hypersensitive
PTPN2-deficient DCs provide an environment of uprising
inflammation, ultimately resulting in systemic inflammation
in aged mice. Endotoxic shock is dependent on IFNγ and
TNF production (39) and IFNγ levels were elevated in
PTPN2fl/fl × CD11cCre mice without any external stimulus.
In vitro, activation of PTPN2-deficient BMDCs with IFNγ
or LPS resulted in increased expression of the co-stimulatory
molecules CD80 and CD86, providing an explanation for the
increased numbers of activated T cells in PTPN2fl/fl × CD11cCre
mice. The important role of exposure to bacterial products
for provoking tissue inflammation in PTPN2fl/fl × CD11cCre
mice was further supported by the observation that systemic
antibiotic treatment prevented the development of inflammation
in PTPN2fl/fl × CD11cCre mice. Thus, continuous exposure
to microbial challenges in skin and liver likely contributed
to the development of severe inflammation in PTPN2fl/fl ×
CD11cCre mice by triggering activation of hypersensitive PTPN2-
deficient DCs.
On a molecular level, the development of systemic
inflammation in PTPN2fl/fl × CD11cCre mice was attributable
to two different factors. Loss of PTPN2 in DCs increased
STAT1 phosphorylation and thus transcription of down-
stream target genes, such as IRF1. Expression of IRF1
induced aberrant, cell-intrinsic DC maturation resulting
in increased expression of co-stimulatory molecules even
without maturation-inducing triggers (28, 29). Additionally,
hypersensitivity to LPS/bacteria further activated PTPN2-
deficient DCs. The lack of a functional feedback loop due to
reduced de-phosphorylation of inflammatory signaling cascades
(i.e., STAT and MAPK signaling) then further promoted an
exaggerated immune response and ultimately the development
of tissue inflammation.
Notably, partial PTPN2-deficiency in DCs did not lead to the
development of severe systemic inflammation in all mice. While
macroscopic changes (i.e., splenomegaly) were consistently
observed in all mice, skin, and liver inflammation occurred
only in ∼40% of PTPN2fl/fl × CD11cCre mice and severity
of inflammation varied from mild and almost undetectable
to very severe and in some cases leading to spontaneous
death. This situation reflects observations in human patients,
where—like in our mouse models with very different disease
kinetics/severity between individuals—not every person carrying
PTPN2 variants ultimately develops inflammatory disorders.
The variation in our model can partially be attributed to
the genetic construct we used, as PTPN2 expression in DCs
was reduced only about 30% compared to DCs from wild-
type mice, thus some DCs retained PTPN2 expression. In
addition, we detected significantly increased PTPN2 expression
in macrophages. Since inflammatory cytokines promote PTPN2
expression, this up-regulation is likely the result of the
inflammatory milieu upon partial PTPN2 deletion in DCs.
Based on our findings, we speculate that a complete deletion
of PTPN2 in DCs might be lethal or lead to very early
onset of systemic inflammation comparable to the inflammation
observed in Ptpn2−/− mice (10). Furthermore, the variable
degree of inflammation might result from varying exposure
to microbes.
We here describe a model for spontaneous inflammation
of skin and liver by specifically, yet partially deleting PTPN2
in DCs. This renders DCs more active and skews the balance
away from immune temperance toward an inflammation-
permissive state. Subsequently, T cells that interact with PTPN2-
deficient DCs are more prone to activation resulting in a
feed-forward cascade that involves T cell and DC signals.
In summary, our data demonstrate a crucial role of PTPN2
in DCs to maintain tissue homeostasis and suggest that
the development of systemic inflammation results from a
generalized loss of immune tolerance upon partial DC-specific
loss of PTPN2. This confirms the importance of PTPN2 in
the field of autoimmune and inflammatory disorders and
highlights its essential, although previously unappreciated, role
in maintaining DC-mediated tissue tolerance. Our results
further indicate that activation of PTPN2 might be a very
promising therapeutic approach for a broad range of chronic
inflammatory and autoimmune disorders, including systemic
lupus erythematosus, type-1-diabetes, rheumatoid arthritis,
and psoriasis.
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